More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$695333608
EPS
-1.76
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.645914
Previous close
$6.48
Today's open
$6.48
Day's range
$6.10 - $6.57
52 week range
$4.16 - $11.45
show more
CEO
Bo Cumbo
Employees
121
Headquarters
Charlestown, MA
Exchange
Nasdaq Global Select
Shares outstanding
111610531
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing
Solid Biosciences NASDAQ: SLDB plans to meet with the U.S. Food and Drug Administration before the end of 2026 to discuss a potential accelerated approval pathway for its Duchenne muscular dystrophy gene therapy, CEO Bo Cumbo said at a Jefferies fireside chat.
MarketBeat • Nov 17, 2026

Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
CHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conference: 2026 Jefferies Global Healthcare Conference in London Bo Cumbo, President and CEO, will participate in a fireside chat on Monday, November 16, 2026, at 2:30 p.m.
GlobeNewsWire • Nov 10, 2026

Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
CHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that members of management will participate in one-on-one investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference taking place in Boston, MA on Monday, November 9, 2026.
GlobeNewsWire • Nov 5, 2026

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -
GlobeNewsWire • Nov 4, 2026

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia
- Obtaining Orphan designation from the European Commission reflects Solid's commitment to the global development of SGT-212 for individuals living with Friedreich's ataxia - - SGT-212 is a first-in-class dual route FA gene therapy designed to combine direct, MRI-guided delivery to the dentate nuclei with systemic delivery to reach cardiac and other systemic tissues - - Five participants have been dosed in the ongoing Phase 1b FALCON clinical trial and SGT-212 has been well tolerated as of October 5, 2026 - - Solid expects to report initial FALCON clinical data in Q1 2027 - CHARLESTOWN, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the European Commission (EC), acting upon the positive opinion of the European Medicines Agency's Committee for Orphan Medicinal Products, has granted Orphan designation to SGT-212 for the treatment of Friedreich's ataxia (FA).
GlobeNewsWire • Oct 26, 2026

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that seven abstracts have been accepted for poster presentation at the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany.
GlobeNewsWire • Oct 20, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee.
GlobeNewsWire • Oct 1, 2026

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations
Solid Biosciences is a speculative buy, leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. SLDB's investment thesis centers on building both biological and controlled functional evidence, not just microdystrophin expression, to address physician and regulatory concerns. Competitive positioning against Sarepta and Regenxbio hinges on achieving clinically meaningful differentiation in function, safety, and eligibility, with time pressure from advancing rivals.
Seeking Alpha • Sep 25, 2026

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha • Sep 10, 2026

Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.
GlobeNewsWire • Sep 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Solid Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.